Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)

NCT00388960 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00388960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00388960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2006
Completion date
December 1, 2010
Enrollment
99 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer